-
UAB Comprehensive Diabetes Center Associate Director Fernando Ovalle, M.D., recently sat down with UAB MedCast podcast to talk about treating Type 2 diabetes in the CDC-coined "Diabetes Belt."
-
This study will enroll patients to evaluate which combination of three proposed interventions — including health coaching, food delivery and remote patient monitoring — will help patients manage diabetes and also be sustainable for health systems to implement.
-
Photo credit: Amy Jones The Bill L. Harbert Institute for Innovation and Entrepreneurship recognized UAB Comprehensive Diabetes Center (UCDC) Director Anath Shalev, M.D., through the EntrepreHER award for Shalev’s leadership in founding a new diabetes startup headquartered in Birmingham, AL.
-
Donnie Bush, who has Type 1 diabetes, and his wife DeDee have endowed a legacy gift to the UAB Comprehensive Diabetes Center to promote cutting-edge diabetes research.
-
Drs. T. Brooks Vaughan (right) and Amy Warriner (left) Each year, the UAB Department of Medicine announces several awards for faculty across many divisions, from research and clinical awards of excellence to unsung heroes to teaching awards.
-
Eugenia Kharlampieva’s commitment to high-caliber diabetes and cancer research using polymer chemistry has earned her recognition as the 2022 Ireland Prize recipient.
-
Pictured: Silverstein family and Dr. Anath Shalev (third from right)The UAB Comprehensive Diabetes Center recently recognized Benny M. LaRussa, Jr., and David L. Silverstein as 2022 Volunteers in Philanthropy at the Association of Fundraising Professionals Alabama Chapter National Philanthropy Day[…]
-
The UAB Comprehensive Diabetes Center is comprised of faculty members conducting basic, translational, and clinical research related to diabetes and its complications. Current areas of research include autoimmune type 1 diabetes, type 2 diabetes, diabetes complications, beta cell biology, oxidative[…]
-
In a new series, the UAB Comprehensive Diabetes Center (UCDC), a leader in the field of diabetes research, will highlight its dynamic faculty and trainees.
-
Endocrinology journal selected a recent paper from the research lab of UAB Comprehensive Diabetes Center Director Anath Shalev, M.D., as the feature article of the week. As the feature article, the team’s research will stay at the top of the[…]
-
UAB Comprehensive Diabetes Center Director Anath Shalev, M.D., recently sat down with UAB MedCast podcast to talk about new frontiers in diabetes research.
-
Three UAB employees share their diabetes journey and provide healthy tips in honor of Diabetes Awareness Month.
-
Ava Michl was traversing her new collegiate world through freshman year at the University of Alabama at Birmingham when she was rocked by an unexpected Type 1 diabetes diagnosis. Up to that point in her life, Michl had no idea[…]
-
One of the UAB Comprehensive Diabetes Center's mission pillars is the training of the next generation of diabetes professionals. In our long-term pursuit of improving the lives of those affected by diabetes, we train undergraduate, graduate students, and postdoctoral scholars as[…]
-
In a new series, the UAB Comprehensive Diabetes Center (UCDC), a leader in the field of diabetes research, will highlight its dynamic faculty and trainees.
-
Department of Psychology Associate Professor Michael Sloane, Ph.D., grew up in the rolling countryside of Ireland, where processed foods were far from a dietary staple– everything was farm to table. His family grew all their own vegetables and fruits, raised[…]
-
The year was 1997. Department of Medicine Communications Director Carolyn Walsh was traveling on i459 when things did not feel quite right. She was fighting to stay awake at the wheel, noticing bouts of drowsiness on and off. Before she[…]
-
The year was 1968, and Donnie Bush found himself in a rural doctor’s office facing a Type 1 diabetes diagnosis. This was still a daunting diagnosis at the time: while treatment options were improving, disposable syringes were not yet widely[…]
-
At their annual Innovation Awards, UAB’s Bill L. Harbert Institute for Innovation and Entrepreneurship celebrated innovators from all corners of campus for their accomplishments, inventions and ingenuity.
-
Given the rising rates of obesity and diabetes, semaglutide could be used effectively to reduce the burden of these chronic diseases.
-
UAB Comprehensive Diabetes Center Graduate Research Assistant and Ph.D. Candidate Tayleur White was awarded a travel award for the 17th Annual Bioactive Lipids in Cancer, Inflammation, and Related Diseases International Conference.
-
Knockout of TXNIP improves diabetes-associated hyperglycemia and hyperglucagonemia.
-
Beta-cell regeneration– an area of research that may feel more science fiction than science today. But, it is a keen area of interest for UAB Comprehensive Diabetes Center (UCDC) researchers using cell biology approaches to discover curative treatments for Type[…]
-
Published results suggest the COVID-19 pandemic exacerbated the slow increase in pediatric Type 2 diabetes.
-
Department of Nutrition Sciences Professor, Tim Garvey, M.D., and team set out to investigate the effects of both cardiometabolic disease (CMD)–such as obesity and type 2 diabetes–and social determinants of health (SDoH)–like educational attainment, social vulnerability index, rurality, and healthcare[…]
-
Carbohydrates are directly linked to the development of Type 2 diabetes, but a higher-carb diet is underused in research models.
-
Seven questions for Michael Sloane, Ph.D., on his seven-year quest to race on every continent.
-
UAB Heersink School of Medicine staff council representatives have officially been named for the 2022-2024 term. See who has been elected to represent you!
-
The Council on Basic Cardiovascular Sciences, known as the BCVS, is one of the largest councils at the American Heart Association, and it is one of the largest organizations in cardiovascular sciences globally, with more than 4,700 members.
-
This therapy, using sustained release of nitric oxide, may be a novel, efficient and safe way to prevent and treat multiple metabolic diseases.
-
Benefits of the blood pressure medication verapamil include delayed disease progression, lowered insulin requirements and preservation of some beta cell function.
-
Record $95 million Heersink lead gift to advance strategic growth and biomedical innovation.
-
Use of the diabetes drug metformin — before a diagnosis of COVID-19 — was associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes.
-
These lipids may act as a biomarker for Type 1 diabetes and offer a therapeutic target to prevent the disease.
-
The drug candidate is a non-toxic small molecule that given orally effectively rescued mice from models of Type 1 and Type 2 diabetes.
-
This award recognizes Robert Oster’s numerous statistical contributions to UAB faculty, staff and students.
-
Impacting the health and well-being of a community is a cornerstone of UAB’s strategic plan and has been recognized globally by Times Higher Education.
-
John Kearney, Ph.D., Distinguished Professor in the Department of Microbiology, will be honored for 45 years of service to UAB during the annual Service Awards banquet March 6.
-
This suggests the possibility of cross-talk that heightens pathogenesis in Type 1 diabetes.
-
Three School of Medicine faculty projects were recently funded as AMC21 2019 Multi-PI awardees.
-
The biomarker can identify beta cell death in children and adults with recent-onset Type 1 diabetes and in antibody-positive at-risk subjects before disease onset.
-
UAB and Children’s of Alabama have named the new director of Pediatric Endocrinology.
-
UAB nutrition researchers are conducting a new study on Type 2 diabetes and addressing the disproportionate complications experienced by African American patients.
-
A new study from UAB describes the impact of a peer coach intervention on hospitalizations and emergency room visits for individuals with diabetes and depression.
-
Some 652 participants across four states will be recruited to test the effects of exercise and diet interventions in underserved cancer survivors.
-
A gene called TXNIP was the answer, and it led to a drug called verapamil and a successful diabetes trial.
-
Significant novel findings published by UAB researchers established verapamil as a successful therapeutic approach to target loss of beta cell function caused by Type 1 diabetes.
-
Inhibition of this microRNA might improve response to newer diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta.
-
Inhibition of this microRNA might improve response to newer diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta.
-
A multidisciplinary research team at UAB looks to address obesity as it is genetically passed from mother to child.
